Metabolomic Technologies Inc. (MTI) Receives US Patent Covering Methods of Assessment of Colorectal Cancer and Colorectal Polyps by Measurement of Metabolites in Urine
EDMONTON, Alberta (PRWEB) April 30, 2019 - MTI, an innovative molecular diagnostics company, announced that the US Patent and Trademark Office has issued patent number 10,267,800 as of April 23, 2019. The patent entitled, “Methods for the Assessment of Colorectal Cancer and Colorectal Polyps by Measurement of Metabolites in Urine”, includes fundamental claims describing methods of analyzing a patient’s urine to detect colorectal cancer and precancerous polyps. The patent carries a term extending to 2033. This patent represents the 20th patent that has been granted for MTI’s PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. Patents have also been issued in Japan, Hong Kong, throughout Europe, Canada and Australia.
“Our innovative new test is a game-changer in the detection and prevention of colorectal cancer”, said Dr. David Chang, Chief Executive Officer for MTI. “We believe this patent acknowledges our unique innovation in colorectal cancer screening and prevention, and importantly, demonstrates our expertise in bringing novel diagnostics from the laboratory to clinically-validated, patient-friendly tests to benefit colorectal cancer screening in the US."